Kornimate/medical-research-clean huggingface dataset:
treatment of intraocular retinoblastoma

Conditions: Retinoblastoma

Summary: this study compares the effects of balloon technology and microcatheter technology on the eye protection rate of neuroblastoma

retinoblastoma is the most common intraocular malignant tumor in childhood, with an incidence of about 1/15,000-20,000, accounting for 4% of all childhood cancers. all patients with bilateral reticuloblastoma and approximately 10%-15% of children with unilateral disease have germline mutations that can be passed on to their offspring.in developed countries, the survival rate is close to 98%. however, due to the limitations of health care in low-income countries, this proportion is much lower, about 40%. before the 1990s, retinoblastoma was mainly treated with enucleation and external beam radiation therapy (ebrt). however, these methods are associated with many complications, including vision loss and serious side effects. at present, the first-line conservative treatment of retinoblastoma has changed from ebrt and enucleation to intravenous chemotherapy (ivc) or intra-arterial chemotherapy (iac), and it has been consolidated through focal treatment. there are two different surgical procedures for intra-arterial chemotherapy, namely balloon technique and microcatheter technique. investigators observe their effects through a retrospective case-control study.

Eligibility criteria:
inclusion criteria: 1. 1 year old \<age ≤ 18 years old; 2. after biopsy, histopathology and immunohistochemistry tests refer to the cog recommended neuroblastoma diagnostic criteria, pathological classification (inpc), and international neuroblastoma staging (inss) 3. patients who were diagnosed with rb for the first time or received chemotherapy in our hospital for the first time after diagnosis 4. ecog scale (ecog-ps) ≤ 2; exclusion criteria: 1. no antibiotics and no gastrointestinal surgery within 3 months. 2. patients with autoimmune diseases; 3. patients with immunodeficiency; 4. patients who have been treated for relapsed/refractory diseases; relapsed nb is the appearance of new lesions at the primary site or other sites 4 weeks after the multidisciplinary comprehensive treatment reaches cr. refractory nb is defined as induced by 2 to 4 courses of treatment the post-effect evaluation is progression disease (pd) during chemotherapy; 5. multiple organ failure; 6. uncontrolled infection and diarrhea

Keywords: retinoblastoma;intravenous chemotherapy;eye protection rate
requests for euthanasia and assisted suicide in establishment of accommodation for dependent old persons.

Conditions: Qualitative Research; Euthanasia; Assisted Suicide; Aging

Summary: the main aim of this project is to analyze and understand the meaning of explicit requests to hasten death (euthanasia and assisted suicide) from older people living in an establishment of accommodation for dependent old persons. this involves conducting interviews with patients, carers to whom the request has been expressed and a relative chosen by the patient. this study aims to describe the request over time. this will be done through two series of interviews, one as soon as it is first expressed, then one week later.


Eligibility criteria:
inclusion criteria: * they live in an establishment of accommodation for dependent old persons * they have to be ill. * they have request for euthanasie or assisted suicide * they are in capacity to meet researchers for interview, * they aggreed to make an individual interview * they are covered by the french social security system exclusion criteria: * they have neurocognitives disorders that can't allow an individual interview * they did not express themselves a request for euthanasia ou assisted suicide * they disagreed to participate
shr-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this is an open label, phase ib study of shr-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(r/m npc).

the main purpose of this study is to assess the safety and tolerability of shr-1701 in patients with r/m npc. the secondary purpose is to assess the anti-tumor activity and immunogenicity of shr-1701 in r/m npc.

Eligibility criteria:
inclusion criteria: * histologically confirmed recurrent/metastatic nasopharyngeal carcinoma * subjects failure after platinum-based chemotherapy; failure from anti-pd-1/pd-l1 antibody therapy; primarily metastatic (stage ivb as defined by the international union against cancer and american joint committee on cancer staging system for npc, eighth edition) or recurrent npc that is not amenable for local regional treatment or curative treatment; failure from first line anti-pd-1/pd-l1 antibody therapy. * able and willing to provide signed informed consent form, and able to comply with all procedures. * histologically or cytologically proven metastatic or locally advanced solid tumors. * life expectancy \>= 12 weeks as judged by the investigator. * eastern cooperative oncology group (ecog) performance status of 0 to 1 at trial entry. * disease must be measurable with at least 1 uni dimensional measurable lesion by response evaluation criteria in solid tumors (recist) version 1.1. * adequate hematological, hepatic and renal function as defined in the protocol other protocol-defined inclusion criteria could apply. exclusion criteria: * prior therapy with an anti-pd1, anti-pd-l1, anti-ctla-4 or a tgfb inhibitor. * anticancer treatment within 28 days before the first dose of study drug. * major surgery within 28 days before start of trial treatment. * systemic therapy with immunosuppressive agents within 7 days prior to the first dose of study drug; or use any investigational drug within 28 days before the start of trial treatment. * with any active autoimmune disease or history of autoimmune disease. * with active central nervous system (cns) metastases causing clinical symptoms or requiring therapeutic intervention. * clinically significant cardiovascular and cerebrovascular diseases * history of immunodeficiency including seropositive for human immunodeficiency virus (hiv), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy. * previous malignant disease (other than the target malignancy to be investigated in the trial) within the last 2 years. subjects with history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are not excluded. * receipt of any organ transplantation, including allogeneic stem-cell transplantation other protocol-defined exclusion criteria could apply

Keywords: nasopharyngeal carcinoma
eicosanoids in human heart failure

Conditions: Heart Failure

Summary: our translational project aims to evaluate the role of eicosanoids in human hf.

heart failure (hf) is the leading cause of cardiovascular hospitalizations, and with its increasing prevalence, the healthcare systems face a heart failure pandemic. translational research findings improve our knowledge of pathophysiology and uncover therapeutic targets in hf. natriuretic peptides represent such examples as routinely used in diagnostics and therapeutics (neprilysin inhibitor). despite modern pharmacotherapy, including angiotensin receptor-neprilysin inhibitor (arni) and sodium-glucose cotransporter-2 inhibitors (sglt2i), the prognosis of patients, especially with advanced heart failure, remains poor. furthermore, most medication is limited in the late stages of hf due to their hypotensive effects. basic research has been focused on the eicosanoids - metabolites of cytochrome p-450 (cyp)-dependent epoxygenase pathway of arachidonic acid (aa), especially epoxyeicosatrienoic acids (eets). in the preclinical studies, it was shown that eets importantly contribute to the regulation of cardiovascular and renal function and exert organ-protective actions. it was also proposed that intrarenal eets operate as an endogenous compensatory system opposing increased renin-angiotensin system (ras) activity. eets are rapidly transformed by soluble epoxide hydrolase (seh) to biologically inactive dihydroxyeicosatrienoic acids (dhets). the role of eicosanoids in human hf, however, remains unclear. our translational project (eicosanoids in human heart failure) aims to evaluate the role of eicosanoids in human hf.

Eligibility criteria:
inclusion criteria: * heart failure exclusion criteria: * none

Keywords: heart failure eicosanoids reverse remodeling
exploratory study evaluating the effects of dermo-cosmetic rv5026b applied for 2 months in adults with erythrocouperosis

Conditions: Erythrocouperose Associated With Pityriasis Folliculorum of the Face

Summary: this exploratory study aims to evaluate the effects of the test product rv5026b - et1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum. we wish to evaluate: * firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face, * then the contribution of the test product in addition to a reference topical treatment. the test product rv5026b - et1732 was developed to: * reduce redness, even if it has already set in, and help limit its reappearance * soothe the sensations of heating and discomfort associated


Eligibility criteria:
main inclusion criteria: * man or woman aged 18 to 75 years old * subject presenting erythrocouperosis associated with pityriasis folliculorum of the face with erythema of mild to severe intensity according to the iga clinical rating on both cheeks * high density of demodex on both cheeks: sssb1 \> 5 d/cm² or sssb2 \> 10 d/cm² main non-inclusion criteria: - subject presenting, on the day of inclusion, a dermatological condition of the face other than that studied 1. oral/general treatments that were planned to be taken during the study or that were taken: a. in the last 3 months: - any change in hormone replacement therapy. - any oral treatment vit a or derivatives b. in the last 4 weeks: - any change in oral drug treatment that could modify the skin characteristics of the subjects and interfere with the performance of the study product - tetracyclines - immunosuppressant - antiparasitic - corticosteroid or nsaid taken for more than 5 consecutive days c. in the last 2 weeks: - antibiotic with known cutaneous impact 2. local treatments that were planned to be taken during the study or that were taken: a. in the last 3 months: - vascular laser of the face b. in the last 4 weeks: - any topical medicinal product on the face that could modify the skin characteristics of the subjects and interfere with the performance of the study product. c. in the last 10 days: - changes to any topical cosmetic product (toiletries, care products and makeup) on the face d. in the last 7 days: * topical antiseptic on the face * any topical cosmetic product applied to the face that could modify the skin characteristics of the subjects and interfere with the performance of the product under study e. since the last wash performed the night before: - application of topical treatment, rinsed or non-rinsed dermocosmetic product on the face
a study of stress echocardiography in post-menopausal women at risk for coronary disease

Conditions: Coronary Artery Disease; Heart Disease

Summary: the study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.

the clinical trial is designed to determine the prognostic value of stress echocardiography as a screening examination in peri-, or post-menopausal female patients with an intermediate likelihood of coronary artery disease (cad) based on risk factors to identify patients at higher risk of experiencing future cardiac events.female patients who are able to adequately exercise will undergo a symptom-limited exercise echocardiogram. patients who are unable to adequately exercise or are predicted to be unable to exercise adequately (because of orthopedic/neurologic limitations, lung disease or debility), will perform dobutamine stress echocardiography. all patients will receive definity at rest and stress to enhance wall motion assessment.

Eligibility criteria:
inclusion criteria: * peri or post menopausal women either: * without symptoms but with risk factors for heart disease or * experiencing atypical chest pain, or * experiencing exertional dyspnea and 2 or more risk factors for cad * must be able to perform an exercise stress test peri-or post-menopausal (including surgical menopause) based on history. * post-menopausal is defined as females age 40-65 who self-report the absence of menstrual periods for at least 12 months. * peri-menopausal is defined as females age 40-65 who self-report the absence or irregularity of menstrual periods for 6-12 months. * surgical menopause is defined as females who have had a bilateral salpingo-oophorectomy with or without hysterectomy. exclusion criteria: * previous confirmed heart disease
combining acitretin and efalizumab in the therapy of chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: it is a phase iv multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis. pasi 75 at week 24 will be the primary end point. pasi 75 at week 12, and pasi 50 at week 24 will be the secondary end points. safety measures will be the monitoring of serum parameters including ast; alt; gammagt; creatinine; cholesterol and triglycerides.


Eligibility criteria:
inclusion criteria: * men aged 18-70 * women in postmenopausal * moderate to severe chronic plaque psoriasis in patients with contraindication, intolerance or non responsive to cyclosporine, methotrexate or puva * pasi \> 10 e/o bsa (body surface area) \> 10 exclusion criteria: * drug induced psoriasis * pustular or erythrodermic psoriasis * fertile women * pregnancy or lactation * cholesterol \> 230mg/dl e triglyceride \> 200 mg/dl * known intolerance to efalizumab and acitretin * serious infection at enrollement * history of previous neoplasia

Keywords: psoriasis acitretin efalizumab
efficacy of vr based sword fighting exercises to improve upper body movements in hemiplegic patients

Conditions: Hemiplegic Gait

Summary: this thesis endeavors to shed light on the efficacy of vr-based sword-fighting exercises as a rehabilitation tool for improving upper body movement in hemiplegic patients.

by amalgamating clinical insights, technological advancements, and theoretical frameworks, this research aims to contribute to the growing body of knowledge in neurorehabilitation and pave the way for innovative, effective, and engaging interventions to enhance the lives of individuals affected by hemiplegia.

Eligibility criteria:
inclusion criteria: * age 21-80 years * first clinical stroke, ischemic or hemorrhagic, with diagnosis of stroke confirmed on ct/mri brain scan. * less than 6 weeks after stroke onset * upper limb weakness of medical research council (mrc) motor power of grade 2-4 motor power in either the shoulder, elbow or the fingers of the hemiplegic upper extremity * subject can understand simple instructions and learn exclusion criteria: * recurrent stroke * history of epilepsy * presence of arthritis or pain in the affected upper limb restricting repetitive exercises * severe aphasia or cognitive impairment, or other psychiatric illnesses that limit the ability to participate or give consent.
dietary assessment and prevalence of refeeding syndrome in high-risk tb patients in chhattisgarh, india

Conditions: Tuberculosis; Refeeding Syndrome; Severe Malnutrition

Summary: severe tuberculosis (tb) leads to wasting and anorexia, increasing risk of the refeeding syndrome (rfs) as defined by current criteria. tb patients have high metabolic rates and require a high calorie diet, with nutritional supplementation programs improving outcomes. bmi inversely correlates with mortality in these patients. risk of rfs, a life-threatening syndrome associated with initiation of feeding after a period of low intake, has not been studied in this population and it is not known whether severely malnourished tb patients benefit from lower caloric intake. this study aimed to examine the prevalence of rfs in tb inpatients in rural india and correlate this with baseline and inpatient caloric intake.


Eligibility criteria:
inclusion criteria: * all adult inpatients admitted to the tb ward * able to take enteral intake exclusion criteria: * unable to take enteral intake
sb-773812 administered in adults with schizophrenia

Conditions: Schizophrenia

Summary: this is a two part study designed to evaluate the safety and efficacy of sb-773812 in the treatment of acute schizophrenia. subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo, sb-773812 60mg or olanzapine 15mg for 12 weeks in part a. an interim analysis will be conducted to assess the efficacy and safety of the sb-773812 60mg dose compared with placebo. based on these data, up to two further doses of sb-773812 will be added to the randomization for part b.


Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria for schizophrenia as defined in dsm-iv. * panss total score of at least 70 at screen and baseline and a minimum score of 4 (moderate) on at least 2 of the following: conceptual disorganization (p2) hallucinatory behaviour (p3) suspiciousness (p6) or unusual thought content (g9) at the screen and baseline visits exclusion criteria: * subjects with a history of epilepsy or other seizure disorder, first episode of schizophrenia or other psychotic disorders (e.g. residual type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, etc.) * bipolar disorder, a history of substance dependence, or a medical or psychiatric disorder that would interfere with the accurate assessment of safety or efficacy are not eligible.

Keywords: schizophrenia panss acute cognition
clinical experience of thalidomide in thalassemic patients

Conditions: Thalassemia, Beta

Summary: objectives primary objective: • to determine the efficacy and safety of the combination therapy of hydroxyurea and thalidomide in beta-thalassemia patients. secondary objective: • to determine the change in liver and spleen size of beta-thalassemia patients on the combination therapy a single-arm non-randomized trial to evaluate the efficacy and safety of combination therapy of hydroxyurea and thalidomide in beta-thalassemia patients. it was a twelve months study. participants were monitored for six months on hydroxyurea alone and then the combination therapy of hydroxyurea and thalidomide for another six months. findings of physical examination, vital signs, laboratory, and ultrasound findings were recorded at baseline, during and end of the study. sample size and population this study included 135 beta-thalassemia patients.

the purpose of the study was to evaluate the efficacy and safety of the combination therapy of hydroxyurea and thalidomide in beta-thalassemia patients. the participants were evaluated on the basis of eligibility criteria, consent was obtained and baseline investigations were performed on the screening visit. participants were continued on hydroxyurea (10-20mg/kg/day) for the first six months and then for the next six months thalidomide (2-5 mg/kg/day) was added to the intervention. aspirin was also added (2-4mg/kg/day). efficacy: maintenance or rise in hemoglobin (hb) levels and changes in transfusion frequency before and after the use of combination therapy was used to evaluate the efficacy of the combination therapy. good responders were the patients who were on transfusion and went off-transfusion after the combination therapy or individuals who were already off transfusion and after combination therapy demonstrated an increase in hb of at least 1gm/dl. responders were those who remained on transfusion on combination therapy but displayed a 50% reduction in blood requirements. whereas, non-responders, were individuals who were off-transfusion before combination therapy and had improvement in hb of \<1gm/dl, or those who remained on transfusion during combination therapy and did not experience transfusion reduction of at least 50%. safety: safety of the drug was evaluated on the basis of the following parameters and intervention was discontinued or put on hold if: * creatinine \>1.1mg/dl, urea \>43mg/dl), * liver function (sgpt \>35mg/l) * absolute neutrophil counts\<2\*109/l * platelets \< 100\*109/l

Eligibility criteria:
inclusion criteria: 1. patients with clinical and genetic diagnosis of β-thalassemia major and intermedia 2. patients who showed partial response or a decline in response to hydroxyurea 3. patients who are not the candidates for the bone marrow transplant procedure. exclusion criteria: 1. married patients 2. patients with comorbidities such as liver, cerebrovascular, cardiovascular, or kidney diseases 3. patients allergic to the drug ingredients 4. patients with mental disorders 5. patients who are enrolled in other clinical trials 6. patients with a history of venous or arterial thrombosis
sarscov2 (covid-19) convalescent plasma (cp) expanded access protocol (eap)

Conditions: COVID; SARSCoV2 Convalescent Plasma

Summary: convalescent plasma has been administered to treat different infectious diseases previously with some success. there is currently no approved and proven treatment options available for the novel coronavirus disease (covid-19 virus). some early data has shown a potential benefit in treating hospitalized patients who have tested positive for covid-19 with convalescent plasma infusions of fresh plasma donated by fully recovered covid-19 patients. the antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the covid-19 virus.

convalescent plasma has been administered to treat different infectious diseases previously with some success. there is currently no approved and proven treatment options available for the novel covid-19 virus. some early data has shown a potential benefit in treating hospitalized patients who have tested positive for covid-19 with convalescent plasma infusions of fresh plasma donated by fully recovered covid-19 patients. the antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the covid-19 virus. the purpose of this trial is to provide expanded access to sarscov2 convalescent plasma (eap) collected from matched donors as described to patients with severe or life-threatening illness owing to covid-19.

Eligibility criteria:
inclusion criteria: * ages 6 and up * willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age); or willing and able to provide assent as required per institutional review board (irb) prior to performing study procedures. * must have laboratory confirmed covid-19 positive test * must have severe or immediately life-threatening covid-19 severe disease is defined as: 1. dyspnea 2. respiratory frequency ≥ 30/min 3. blood oxygen saturation ≤ 93% 4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or 5. lung infiltrates \> 50% within 24 to 48 hours life-threatening disease is defined as: 6. respiratory failure 7. septic shock, and/or 8. multiple organ dysfunction or failure exclusion criteria: * known contraindication to transfusion or history of prior reactions to transfusion of blood products